ライフサイエンスコーパス: cholecalciferol

1 all women received supplemental calcium and cholecalciferol.

2 t containing 500 mg of calcium and 250 IU of cholecalciferol.

3 placebo group, none of which were related to cholecalciferol.

4 ons needed for the colorimetric detection of cholecalciferol.

5 150,000 IU (0.15 mU) or 300,000 IU (0.3 mU) cholecalciferol.

6 n subjects received placebo, and 25 received cholecalciferol.

7 rease in vitamin D receptor expression after cholecalciferol.

8 itamin D (calcidiol) to a large oral dose of cholecalciferol.

9 mented with a single oral dose of 100,000 IU cholecalciferol.

10 ciferol group (n = 184) (placebo: 0.16 0.92; cholecalciferol: -0.16 1.06; P-difference < 0.01).

11 Patients were randomized 1:1 to receive oral cholecalciferol 100 000 IU (n = 163) or placebo (n = 153

12 Oral cholecalciferol 100 000 IU every 2 weeks significantly r

13 tients were randomized to receive placebo or cholecalciferol (100,000 IU load plus 4,000 IU/d) for 28

14 Cholecalciferol (100,000 IU) is a safe, effective, and s

15 Vitamin D (cholecalciferol, 100 000 IU, loading dose, followed by 2

16 Supplementation with cholecalciferol 1000 IU/d during pregnancy resulted in g

17 y BMC of infants born to mothers assigned to cholecalciferol 1000 IU/day did not significantly differ

18 Supplementation of women with cholecalciferol 1000 IU/day during pregnancy did not lea

19 n randomly permuted blocks of ten, to either cholecalciferol 1000 IU/day or matched placebo, taken or

20 ned 569 pregnant women to placebo and 565 to cholecalciferol 1000 IU/day.

21 during winter and randomly assigned to oral cholecalciferol (1000 IU/day) versus placebo for 1 month

22 fter stratification by sex to receive either cholecalciferol (1200 IU/d) or a placebo for 16 wk.

23 ive, in addition to teriparatide and 1000 IU cholecalciferol, 1800 mg calcium/d as either tricalcium

24 1 ratio to either (1) thrice-weekly 3,000-IU cholecalciferol, (2) once-monthly cholecalciferol (equiv

25 All capsules also included cholecalciferol, 200 IU.

26 cts of randomized vitamin D supplementation (cholecalciferol), 2000 IU/d, reduced the risk of several

27 randomized to receive either placebo or oral cholecalciferol, 2000 IU/d, with dose escalation to elev

28 e either two directly observed oral doses of cholecalciferol (300,000 IU) or matching placebo at base

29 All patients were prescribed vitamin D(3) (cholecalciferol) 400 IU and calcium carbonate 1,000 mg d

30 In this study, we examined the effects of cholecalciferol, a primary keratinocyte metabolite and p

31 At follow-up, 90.5% of subjects treated with cholecalciferol achieved serum 25(OH)D concentrations >/

32 Cholecalciferol also suppressed intact PTH only among pa

33 ly supplemented with the vitamin D precursor cholecalciferol, although it is unclear whether this reg

34 All patients received 800 IU of cholecalciferol and 1,000 mg of calcium carbonate.

35 term hemodialysis and assessed changes after cholecalciferol and paricalcitol therapies in both vitam

36 ls, gamma-oryzanols, phytosterols, squalene, cholecalciferol and phylloquinone were developed using H

37 e of iodine, cis/trans isomerisation of both cholecalciferol and pre-vitamin D3 takes place to form t

38 factorial design to vitamin D3 (2000 IU/d of cholecalciferol) and fish oil or placebo; 9181 were rand

39 change in biomarkers for placebo, 200,000 IU cholecalciferol, and 400,000 IU cholecalciferol groups,

40 nonsignificant for calcium supplementation, cholecalciferol, and among men.

41 -3189 mug g(-1) squalene, ND-105.3 mug g(-1) cholecalciferol, and ND-54.4 mug g(-1) phylloquinone).

42 Metabolites of vitamin D3 (D3) (cholecalciferol) are recognized as enzymatically formed

43 One gram of calcium per day and oral cholecalciferol at a dosage of 100,000 IU every 2 mo adm

44 wo-by-two factorial design, of vitamin D(3) (cholecalciferol) at a dose of 2000 IU per day and marine

45 ,4-trideuterobutyl)-23-yn e-26,27-hexafluoro-cholecalciferol (BXL0124), on mammary tumor growth and C

46 0 ng/mL) patients with SLE were treated with cholecalciferol by their physician.

47 an adults and how daily supplementation with cholecalciferol changes these concentrations.

48 single dose of either dose of intramuscular cholecalciferol corrected vitamin D deficiency in the ma

49 re injected with either 1alpha,25-dihydroxy- cholecalciferol, cyclosporine A, or interleukin-10.

50 =1000 IU (25 microg) [corrected] vitamin D (cholecalciferol)/d is needed to bring vitamin D concentr

51 e-blind, placebo-controlled trial of 1000 IU cholecalciferol/d compared with placebo from 14 weeks of

52 0,000 IU cholecalciferol followed by 4000 IU cholecalciferol/d or a matching placebo for 16 wk.

53 Healthy men seem to use 3000-5000 IU cholecalciferol/d, apparently meeting > 80% of their win

54 d with placebo, but did show that 1000 IU of cholecalciferol daily is sufficient to ensure that most

55 eatinine; P = 0.03 for placebo compared with cholecalciferol difference in CTX at 34 weeks of gestati

56 Serum calcidiol rose promptly after cholecalciferol dosing from a mean (+/-SD) baseline of 2

57 iferol-induced PGE2 production by inhibiting cholecalciferol-enhanced COX-2 mRNA and protein expressi

58 tion is primarily COX-2 dependent, and (iii) cholecalciferol enhances both COX-2 mRNA and protein exp

59 y 3,000-IU cholecalciferol, (2) once-monthly cholecalciferol (equivalent to 9,000 IU/week), (3) thric

60 uded chlorthalidone, amlodipine, carvedilol, cholecalciferol, erythropoietin, and a phosphate binder.

61 ceive either a bolus oral dose of 100,000 IU cholecalciferol followed by 4000 IU cholecalciferol/d or

62 30,000 (n = 215) or 60,000 (n = 215) IU oral cholecalciferol for </=12 mo.

63 In SLE patients treated with cholecalciferol for 12 weeks, the improvement in endothe

64 doses labeled at 0, 25, 125, and 250 micro g cholecalciferol for approximately 20 wk during the winte

65 kly oral 50 000 IU vitamin D(3) supplements (cholecalciferol) for the first month of ART followed by

66 re post-partum haemorrhage than those in the cholecalciferol group (96 [17%] of 569 mothers in the pl

67 r in the placebo group (n = 188) than in the cholecalciferol group (n = 184) (placebo: 0.16 0.92; cho

68 placebo group and 367 (65%) neonates in the cholecalciferol group had a usable DXA scan and were ana

69 cebo group vs 65 [12%] of 565 mothers in the cholecalciferol group; p=0.01).

70 , 200,000 IU cholecalciferol, and 400,000 IU cholecalciferol groups, respectively, were as follows: 1

71 People who were randomly assigned 60,000 IU cholecalciferol had nonsignificant 28% lower risk of hav

72 2 diabetes, short-term supplementation with cholecalciferol improved beta cell function and had a ma

73 supplemental vitamin D (dietary supplement, cholecalciferol) improves the chemosensitivity of tumors

74 dependently, suggesting a potential role for cholecalciferol in regulating the differentiation of hum

75 concentrations, there is very little native cholecalciferol in the body, and 25(OH)D constitutes the

76 Cholecalciferol increased serum 1,25(OH)(2)D levels, res

77 Furthermore, cholecalciferol increased total cellular transglutaminas

78 Cholecalciferol induced PGE2 production, whereas 1alpha,

79 in kinase C inhibitor, significantly reduced cholecalciferol-induced PGE2 production by inhibiting ch

80 uce PGE2 biosynthesis in keratinocytes, (ii) cholecalciferol-induced PGE2 production is primarily COX

81 e quantitative relation between steady state cholecalciferol input and the resulting serum 25-hydroxy

82 ly 0.70 nmol/L for each additional 1 micro g cholecalciferol input.

83 The cholecalciferol inputs required to achieve or maintain a

84 nic HF due to LVSD and vitamin D deficiency (cholecalciferol <50 nmol/l [<20 ng/ml]).

85 Placebo (n = 10) versus 200,000 IU cholecalciferol (n = 10) versus 400,000 IU cholecalcifer

86 U cholecalciferol (n = 10) versus 400,000 IU cholecalciferol (n = 10), within 24 hours of new-onset s

87 88): from 223.6 to 449.7 ug/mmol creatinine; cholecalciferol (n = 184): from 222.3 to 419.3 ug/mmol c

88 /d, apparently meeting > 80% of their winter cholecalciferol need with cutaneously synthesized accumu

89 secondary aim was to determine the effect of cholecalciferol on blood pressure and serum fibroblast g

90 The effect of pregnancy cholecalciferol on bone outcomes was similar at ages 4 a

91 either placebo or a high dose of vitamin D3 (cholecalciferol) one hour after experimental sunburn ind

92 or uncontrolled-trials with vitamin D terms: cholecalciferol or hydroxycholecalciferols or calcifedio

93 ) were randomly assigned to either 1000 IU/d cholecalciferol or placebo from 14 to 17-wk gestation un

94 Daily cholecalciferol or placebo with assessment of statin pre

95 Monthly augmentation with 120 000 IU of cholecalciferol or placebo.

96 Cholecalciferol or vitamin D3 is known to isomerise unde

97 eceive either weekly vitamin D(3) (15,000 IU cholecalciferol) or placebo capsules for 12 mo.

98 rs the cutaneous production of vitamin D(3) (cholecalciferol) or the intestinal absorption of vitamin

99 eers, supplementation of vitamin D3 (4000 IU cholecalciferol per day) increased the number of circula

100 500 mg of calcium plus 700 IU of vitamin D3 (cholecalciferol) per day or placebo.

101 re correlated in both placebo (r = 0.31) and cholecalciferol (r = 0.45) groups (P < 0.0001).

102 After 1 y, this oral cholecalciferol regimen was safe and sufficient to maint

103 3 months with a low, medium or high dose of cholecalciferol, representative of vitamin D deficiency,

104 ily requirement during winter that is met by cholecalciferol reserves in body tissue stores.

105 [1, 25(OH)2-16,23E-diene-26-trifluoro-19-nor-cholecalciferol (Ro 25-9716)] had an ED50 of 4 x 10(-11)

106 nd the analogue 1,25-dihydroxy-16-ene-23-yne-cholecalciferol (Ro23-7553) have significant in vitro an

107 mount of vitamin D (511 IU/d from diet and a cholecalciferol supplement) for 10 wk.

108 31.6 were randomly assigned to receive daily cholecalciferol supplementation at 1 of 2 doses (2000 or

109 Maternal cholecalciferol supplementation during lactation using a

110 We aimed to determine whether high-dose cholecalciferol supplementation for 1 y in early CKD is

111 Cholecalciferol supplementation increased total and meas

112 In conclusion, cholecalciferol supplementation increases serum hepcidin

113 emonstrated a positive effect of gestational cholecalciferol supplementation on offspring bone minera

114 l trial, we investigated the effects of oral cholecalciferol supplementation on serum hepcidin and pa

115 trolled trial, we investigated the effect of cholecalciferol supplementation on vascular function in

116 High-dose cholecalciferol supplementation rapidly and safely impro

117 Compared with the placebo, weekly cholecalciferol supplementation resulted in greater incr

118 Gestational cholecalciferol supplementation resulted in higher WBLH

119 Cholecalciferol supplementation resulted in increased se

120 Cholecalciferol supplementation significantly increased

121 although to a lesser degree with gestational cholecalciferol supplementation, and is inversely associ

122 IU/d compared with 400 IU/d of vitamin D(3) (cholecalciferol) supplementation in infancy (1-12 mo) on

123 nd efficacy of high-dose 25 (OH) vitamin D3 (cholecalciferol) supplementation in patients with chroni

124 Cholecalciferol therapy increased serum 25(OH)D levels f

125 Cholecalciferol therapy reduced circulating levels of in

126 -IU dose of vitamin D(3) had a rise in serum cholecalciferol to a mean of 521 nmol/L at 1 d and then

127 human trophoblasts were incubated with (13)C-cholecalciferol to examine the intracellular generation

128 obin concentrations, which were lower in the cholecalciferol-treated group (P < 0.04).

129 In cholecalciferol-treated patients, change in 25-hydroxyvi

130 accharide model, 1,500 IU of intraperitoneal cholecalciferol treatment 6 hours postinjury reduced alv

131 Short-term, high-dose oral cholecalciferol treatment of vitamin D deficiency in hem

132 Furthermore, serum PTH improved after cholecalciferol treatment, particularly in patients who

133 1 expression did not increase in response to cholecalciferol treatment.

134 protein expression increased in response to cholecalciferol treatment.

135 4A1 gene transcript abundance in response to cholecalciferol treatment.The numerous associations of m

136 ssion levels did not increase in response to cholecalciferol treatment; however, unlike COX-1 and cPL

137 Vitamin D (cholecalciferol, up to 500 IU/d) was provided if baselin

138 CKD (stages 2-3) were supplemented with oral cholecalciferol (vitamin D group; 50,000 IU/wk for 12 wk

139 ertain the efficacy of weekly very-high-dose cholecalciferol (vitamin D(3)) in correcting vitamin D i

140 at late summer and after 6-mo consumption of cholecalciferol (vitamin D(3))-fortified bread and milk.

141 All participants were prescribed daily cholecalciferol (vitamin D) and calcium.

142 ntrations of ergocalciferol (vitamin D2) and cholecalciferol (vitamin D3) (vitamin D) and 25-hydroxiv

143 pants were randomly assigned to receive oral cholecalciferol (vitamin D3) supplements of 400 IU/d (n=

144 0/0, 16,800/0, 28,000/0, or 28,000/28,000 IU cholecalciferol (vitamin D3)/wk until 26 wk postpartum.

145 levels were higher at Day 3 in the combined cholecalciferol (vs.

146 Cholecalciferol was administered daily in controlled ora

147 hether oral supplementation of vitamin D(3) (cholecalciferol) will reduce the incidence and severity